| Bioactivity | PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells[1]. |
| Invitro | PhAc-ALGP-Dox 通过一个肿瘤特异性的两步切割过程依次被激活，首先由细胞外的 THOP1 启动切割，然后由 FAPα/DPP4 进一步处理[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PhAc-ALGP-Dox 相关抗体: |
| CAS | 1616592-31-4 |
| Sequence | {Phosphonoacetyl}-Ala-Leu-Gly-Pro-{Dox} |
| Shortening | {Phosphonoacetyl}-ALGP-{Dox} |
| Formula | C45H58N5O19P |
| Molar Mass | 1003.94 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Andrea Casazza, et al. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Mol Cancer Ther. 2022 Apr 1;21(4):568-581. |
PhAc-ALGP-Dox
CAS: 1616592-31-4 F: C45H58N5O19P W: 1003.94
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.